Using pooled data, the results showed that TERT promoter mutation positive patients were more likely to relapse bladder cancer according to the meta-analysis (HR: 2.03, 95% CI: 1.53–2.68, p < 0.001, Figure 3a). This evidence concerns the gene TERT and urinary bladder cancer.